Quick Answer
Karyopharm Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $60.54 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -3.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $764.0 thousand | Q2 2013: $17.67 million | Q3 2013: $52.93 million | Q1 2014: $144.89 million | Q2 2014: $132.31 million | Q3 2014: $227.13 million | Q1 2015: $51.45 million | Q2 2015: $24.23 million | Q3 2015: $43.50 million | Q1 2016: $42.19 million | Q2 2016: $37.72 million | Q3 2016: $43.91 million | Q1 2017: $25.58 million | Q2 2017: $55.38 million | Q3 2017: $54.45 million | Q1 2018: $37.50 million | Q2 2018: $118.97 million | Q3 2018: $101.60 million | Q1 2019: $83.51 million | Q2 2019: $75.55 million | Q3 2019: $168.00 million | Q1 2020: $202.25 million | Q2 2020: $103.10 million | Q3 2020: $82.30 million | Q1 2021: $88.47 million | Q2 2021: $141.31 million | Q3 2021: $137.40 million | Q1 2022: $153.26 million | Q2 2022: $82.25 million | Q3 2022: $71.35 million | Q1 2023: $84.06 million | Q2 2023: $80.89 million | Q3 2023: $43.66 million | Q1 2024: $30.63 million | Q2 2024: $84.77 million | Q3 2024: $72.83 million | Q1 2025: $38.78 million | Q2 2025: $38.73 million | Q3 2025: $37.67 million.
- Over the full 16 years of available data (2010 to 2025), Karyopharm Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,657.3%.
- Historical annual values: Fiscal year 2025: $60.54 million | Fiscal year 2024: $62.48 million | Fiscal year 2023: $52.23 million | Fiscal year 2022: $135.19 million | Fiscal year 2021: $190.46 million | Fiscal year 2020: $85.92 million | Fiscal year 2019: $128.86 million | Fiscal year 2018: $118.02 million | Fiscal year 2017: $69.00 million | Fiscal year 2016: $49.66 million | Fiscal year 2015: $58.36 million | Fiscal year 2014: $150.61 million | Fiscal year 2013: $155.97 million | Fiscal year 2012: $391.0 thousand | Fiscal year 2011: $6.51 million | Fiscal year 2010: $3.45 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: